Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting

References

• RicheldiL, CostabelU, SelmanM, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087. doi:10.1056/NEJMoa110369021992121
   PubMed Web of Science ®Google Scholar
• RicheldiL, Du BoisRM, RaghuG, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082. doi:10.1056/NEJMoa140258424836310
   PubMed Web of Science ®Google Scholar
• RicheldiL, CottinV, Du BoisRM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79. doi:10.1016/j.rmed.2016.02.00126915984
   PubMed Web of Science ®Google Scholar
• AzumaA, TaniguchiH, InoueY, et al. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: a subgroup analysis of the INPULSIS® randomized trials. Respirology. 2017;22(4):750–757. doi:10.1111/resp.1296027997064
   PubMed Web of Science ®Google Scholar
• CrestaniB, HugginsJT, KayeM, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60–68. doi:10.1016/S2213-2600(18)30339-430224318
   PubMed Web of Science ®Google Scholar
• SongJW, OguraT, InoueY, et al. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: results from INPULSIS®-ON. Respirology. 2020;25(4):410–416. doi:10.1111/resp.1364731329360
   PubMed Web of Science ®Google Scholar
• RicheldiL, KreuterM, SelmanM, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581–583. doi:10.1136/thoraxjnl-2016-20970128993537
   PubMed Web of Science ®Google Scholar
• OishiK, HiranoT, MurataY, et al. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study. Ther Adv Respir Dis. 2019;13:1753466619872890. doi:10.1177/175346661987289031476961
   PubMed Web of Science ®Google Scholar
• OkuH, ShimizuT, KawabataT, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408. doi:10.1016/j.ejphar.2008.06.04618598692
   PubMed Web of Science ®Google Scholar
• InomataM, NishiokaY, AzumaA. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid. 2015;10:89–98. doi:10.2147/CE.S8290526346347
   PubMed Web of Science ®Google Scholar
• KingJT, BradfordWZ, Castro-BernardiniS, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092. doi:10.1056/NEJMoa140258224836312
   PubMed Web of Science ®Google Scholar
• IkedaS, SekineA, BabaT, et al. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis. Sci Rep. 2017;7:10811. doi:10.1038/s41598-017-11321-x28883482
   PubMed Web of Science ®Google Scholar
• KatoM, SasakiS, NakamuraT, et al. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep. 2019;9:12062. doi:10.1038/s41598-019-48593-431427707
   PubMed Web of Science ®Google Scholar
• RaghuG, CollardHR, EganJJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. doi:10.1164/rccm.2009-040GL21471066
   PubMed Web of Science ®Google Scholar
• MahlerDA, WellsCK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580–586. doi:10.1378/chest.93.3.5803342669
   PubMed Web of Science ®Google Scholar
• OkenMM, CreechRH, TormeyDC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655. doi:10.1097/00000421-198212000-000147165009
   PubMed Web of Science ®Google Scholar
• Du BoisD, Du BoisEF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–871. doi:10.1001/archinte.1916.00080130010002
   Google Scholar
• RyersonCJ, VittinghoffE, LeyB, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145:723–728. doi:10.1378/chest.13-147424114524
   PubMed Web of Science ®Google Scholar
• ChaudharyNI, RothGJ, HilbergF, et al. Inhibition of PDGF, VEGF and FGF signaling attenuates fibrosis. Eur Respir J. 2007;29:976–985. doi:10.1183/09031936.0015210617301095
   PubMed Web of Science ®Google Scholar
• HilbergF, RothGJ, KrssakM, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782. doi:10.1158/0008-5472.CAN-07-630718559524
   PubMed Web of Science ®Google Scholar
• EllisPM, KaiserR, ZhaoY, StopferP, GyorffyS, HannaN. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res. 2010;16(10):2881–2889. doi:10.1158/1078-0432.CCR-09-294420460487
   PubMed Web of Science ®Google Scholar
• ReckM, KaiserR, EschbachC, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011;22(6):1374–1381. doi:10.1093/annonc/mdq61821212157
   PubMed Web of Science ®Google Scholar